Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Feb 23, 2023 5:22am
51 Views
Post# 35300020

RE:Deadlines, facts, and distortions

RE:Deadlines, facts, and distortions
GrahamB wrote:

Deadlines

 

I love deadlines . I like the whooshing sound they make as they fly by.

Douglas Adams

 

 

Right, so there was no deadline. There was no expectation that September was the month to receive news that was going to be pivotal, that was going to lead to transformation the share price, that was going to lead to happy times. (See my previous post-statements WERE made but we can pretend it doesnt exist)

 

 

OK let’s reset. How about we set some new deadlines, just so we have something to guide us. OK so we are looking for November 1 for an NICE report

 

It has been touted that this will be transformational because it means that it will be  approved, lead to a standard of care, and the UK will require people to purchase units throughout the country. 

 

Problem is the first assertion is an assumption, and the second just isnt true.

 

This is not a NICE review but a  Medtech innovation briefings (MIBs) which are NICE advice. The difference between the two is significant, since MIBs do not result have the same importance of formal NICE guidance, and do not contain new NICE recommendations.Ergo no guidance to provide machines, which is being promoted here and on ceo.ca, Which would’ve had profound significance for Sales if this were true.

Problem is-its more fluff -imo

 

 

Get your facts first, then you can distort them as you please.

Mark Twain

 

Borrowing from the wisdom of Mark Twain,  perhaps we can isolate facts, and establish deadlines to facilitate a meaningful fact based discussion of equities, and VPT in particular.

 

I’ll be signing off again, until there are some facts. 

 

This being financials, meaningful news releases that indicate sales, the GE alliance finally being announced -if that occurs-and the terms of that, or perhaps in November when we hear that the NICE report will be issued.

 

Will any of these materialize ?

Many guarantee it here-or suggest it-yet these predictions have failed again, and again

Thems the facts

 

Ok see everyone in a month or so



So- the negative NICE report was a "clerical error", now withdrawn because it doesnt matter.

Yet we were told it was the gateway to UK sales

Why did it get withdrawn?

Why would there be a buyout if an evidenced based organization gives a negative report and minimal demand/sales?

Looking forward to hearing more, seeing data of real sales

Thats just me. IMO



<< Previous
Bullboard Posts
Next >>